

## INDEX

### A

Abscess: renal, after renal artery embolization, Nov. 49-50

Acromegaly, Feb. 11-13  
categorization of tumor in, Feb. 12

etiology, Feb. 13

pituitary lesion in, immunocytochemistry of, Feb. 13

surgery results, Feb. 12

Adenocarcinoma: cervix, uterine artery infusion in, Dec. 28

Adenoma  
abnormal events in pancreas leading to, Sept. 25

beta cell, Sept. 13

pancreatic, solitary, Sept. 18

islet cell

beta, hyperfunctioning, Sept. 19

solitary, Sept. 12

solitary, blush of, Sept. 14

nonfunctioning, Feb. 15-16

null cell, Feb. 15-16

pituitary (see Pituitary, adenoma)

prolactin, Feb. 13-14

surgery results, Feb. 14

Adenomatosis  
multiple endocrine, Sept. 30-31

pancreatic beta cell, Sept. 18-21

Adrenal  
-hypothalamic-pituitary axis, Feb. 8

neuroblastoma (see Neuroblastoma, adrenal)

Age  
at diagnosis in thyroid carcinoma, Aug. 26

medulloblastoma and (see under Medulloblastoma)

thyroid carcinoma survival by, Aug. 42-43

Air studies: in medulloblastoma, May 39

Alkaloids: plant, nephrotoxicity of, Oct. 21-22

Alkylating agents: nephrotoxicity, Oct. 5-10

Angiofibroma of nasopharynx, Dec. 45-47

diagnosis, Dec. 45-46

intra-arterial chemotherapy of, Dec. 46-47

Angiography  
cerebellar, in medulloblastoma, May 37-39

iliac, of sacral giant cell tumor, Dec. 15

of melanoma, Dec. 31-33

Anthracyclines: nephrotoxicity, Oct. 18

Antibiotics: antitumor, nephrotoxicity, Oct. 18-21

Antibodies: insulin, measurement, Sept. 9-10

Antidiuretic hormone, Feb. 6

Antigens: sarcoma-associated, in urine, evaluation, Mar. 9

Antimetabolites: nephrotoxicity, Oct. 13-18

Antineoplastic drugs  
for intra-arterial infusion, Nov. 6-7

nephrotoxicity of, Oct. 3-32

Antitumor antibiotics: nephrotoxicity, Oct. 18-21

Apudoma, Nov. 42-44

hepatic artery infusion in complications, Nov. 43

results, Nov. 43

Arteries  
auricular, Dec. 39

carotid, external, Dec. 39

facial, Dec. 39

gastroduodenal, occlusion in hepatic artery infusion chemotherapy, Nov. 14

gluteal, occlusion for infusion in carcinoma of cervix, Dec. 21

hepatic (see Hepatic artery)

iliac, infusion by, Nov. 13

## INDEX

### A

Abscess: renal, after renal artery embolization, Nov. 49-50

Acromegaly, Feb. 11-13  
categorization of tumor in, Feb. 12

etiology, Feb. 13

pituitary lesion in, immunocytochemistry of, Feb. 13

surgery results, Feb. 12

Adenocarcinoma: cervix, uterine artery infusion in, Dec. 28

Adenoma  
abnormal events in pancreas leading to, Sept. 25

beta cell, Sept. 13

pancreatic, solitary, Sept. 18

islet cell

beta, hyperfunctioning, Sept. 19

solitary, Sept. 12

solitary, blush of, Sept. 14

nonfunctioning, Feb. 15-16

null cell, Feb. 15-16

pituitary (see Pituitary, adenoma)

prolactin, Feb. 13-14

surgery results, Feb. 14

Adenomatosis  
multiple endocrine, Sept. 30-31

pancreatic beta cell, Sept. 18-21

Adrenal  
-hypothalamic-pituitary axis, Feb. 8

neuroblastoma (see Neuroblastoma, adrenal)

Age  
at diagnosis in thyroid carcinoma, Aug. 26

medulloblastoma and (see under Medulloblastoma)

thyroid carcinoma survival by, Aug. 42-43

Air studies: in medulloblastoma, May 39

Alkaloids: plant, nephrotoxicity of, Oct. 21-22

Alkylating agents: nephrotoxicity, Oct. 5-10

Angiofibroma of nasopharynx, Dec. 45-47

diagnosis, Dec. 45-46

intra-arterial chemotherapy of, Dec. 46-47

Angiography  
cerebellar, in medulloblastoma, May 37-39

iliac, of sacral giant cell tumor, Dec. 15

of melanoma, Dec. 31-33

Anthracyclines: nephrotoxicity, Oct. 18

Antibiotics: antitumor, nephrotoxicity, Oct. 18-21

Antibodies: insulin, measurement, Sept. 9-10

Antidiuretic hormone, Feb. 6

Antigens: sarcoma-associated, in urine, evaluation, Mar. 9

Antimetabolites: nephrotoxicity, Oct. 13-18

Antineoplastic drugs  
for intra-arterial infusion, Nov. 6-7

nephrotoxicity of, Oct. 3-32

Antitumor antibiotics: nephrotoxicity, Oct. 18-21

Apudoma, Nov. 42-44

hepatic artery infusion in complications, Nov. 43

results, Nov. 43

Arteries  
auricular, Dec. 39

carotid, external, Dec. 39

facial, Dec. 39

gastroduodenal, occlusion in hepatic artery infusion chemotherapy, Nov. 14

gluteal, occlusion for infusion in carcinoma of cervix, Dec. 21

hepatic (see Hepatic artery)

iliac, infusion by, Nov. 13

intra-arterial (*see* Intra-arterial)  
lingual, Dec. 39  
maxillary, Dec. 39  
occipital, Dec. 39  
pharyngeal, Dec. 39  
renal (*see* Kidney, carcinoma, renal artery embolization)  
stenotic segment, catheterization through, Nov. 16  
temporal, Dec. 39  
thyroidal, Dec. 39  
uterine, in infusion of adenocarcinoma of cervix, Dec. 28

Arteriography: in islet cell adenoma, Sept. 14

L-Asparaginase: nephrotoxicity, Oct. 16

Astrocytoma: cerebellar, differential diagnosis, May 37

Auricular artery, Dec. 39

5-Azacytidine: nephrotoxicity, Oct. 15

## B

Basal cell nevoid: and cerebellar medulloblastoma, May 8-9

BCNU: with cisplatin in brain tumors, Dec. 38

Beta cell adenoma (*see under* Adenoma)  
adenomatosis, pancreatic, Sept. 18-21  
carcinoma, pancreatic, Sept. 18

Beta islet cell carcinoma, Sept. 35  
hyperplasia, Sept. 21

Biologic effectiveness, relative, July 19-20  
expression of energy exchange, July 17-19

Biopsy aspiration cytology, in thyroid carcinoma, Aug. 23-25  
bone core, in hairy cell leukemia, Jan. 8  
in soft tissue sarcoma of extremity, Mar. 13-14

interpretation, Mar. 14-15

Bladder carcinoma (*see below*)  
in rhabdomyosarcoma, Apr. 40  
tumors, and rhabdomyosarcoma, Apr. 36-38

Bladder carcinoma, Dec. 17-26  
cisplatin in, Dec. 22-24  
chemotherapy, details concerning, Dec. 23  
complications, Dec. 23-24  
cisplatin in, intra-arterial and systemic, Dec. 25-26  
chemotherapy, details concerning, Dec. 25  
complications, Dec. 25-26  
results, Dec. 25

cisplatin in, results, Dec. 23

evaluation methods, Dec. 19

5-fluorouracil in, Dec. 24-25  
chemotherapy, details concerning, Dec. 24  
complications, Dec. 25  
results, Dec. 24-25

heparinization in, systemic, Dec. 22

intra-arterial chemotherapy of, Dec. 19-26  
isotopic monitoring of flow distribution, Dec. 22  
technical considerations, Dec. 19-22

radiography of, Dec. 19

staging system, Dec. 18

Bleeding (*see* Hemorrhage)

Blood volume: homeostatic control, Feb. 7

Bone core biopsy, in hairy cell leukemia, Jan. 8  
eosinophilic granuloma (*see* Eosinophilic granuloma of bone)  
marrow, in hairy cell leukemia, Jan. 7-11

metastases from kidney carcinoma, embolization of, Nov. 53

sarcoma, staging system, Mar. 18

scans in medulloblastoma, May 40

Brain  
  scan in medulloblastoma, May 37  
  tumors, Dec. 33-39  
    cisplatin in, Dec. 36-38  
    cisplatin plus BCNU in, Dec. 38  
    etoposide-VP16 in, Dec. 38  
    intra-arterial chemotherapy of, Dec. 34-39  
    intra-arterial chemotherapy of, results, Dec. 36-39  
    intra-arterial chemotherapy of, technical considerations, Dec. 36  
    metastatic, cisplatin in, Dec. 37-38  
Breast carcinoma, Nov. 40-42  
  hepatic artery embolization in, Nov. 41-42  
  hepatic artery infusion in, Nov. 40-41  
  intra-arterial therapy in, Nov. 42  
  liver metastases from, Nov. 40  
  hepatic artery infusion in, Nov. 42

## C

Calcium: infusion test, Sept. 12-13  
Cancer  
  CNS  
    basal cell nevoid associated with, May 8-9  
    conditions associated with May 6-7  
    familial aggregation, May 7  
    hereditary factors in, May 7  
    incidence, May 9-11  
    embolization in (see Embolization)  
    infarction in, Nov. 4-62, Dec. 4-55  
    infusion in (see Infusion)  
    isolation-perfusion in, Nov. 17-18  
    late, after radiation, June 11  
    liver (see Liver, cancer)  
    radiation in (see Radiation, in cancer)

radiotherapy (see Radiotherapy, cancer)  
three most common, in adults and children, May 6  
volume doubling times, July 21  
Carcinoid: of lung, liver  
  metastases from, hepatic artery embolization in, Nov. 44  
Carcinoma  
  bladder (see Bladder carcinoma)  
  breast (see Breast, carcinoma)  
  cervix (see Cervix, carcinoma)  
  colon (see Colon, carcinoma)  
  hepatocellular, Nov. 35-36  
  islet cell, beta, Sept. 35  
  kidney (see Kidney, carcinoma)  
  pancreas, beta cell, Sept. 18  
  rectosigmoid, hemorrhage in, embolization of, Nov. 23  
  rectum, Nov. 36-40  
    hepatic artery infusion in, adjuvant, Nov. 37-38  
  thyroid (see Thyroid carcinoma)  
Care: city and health, in thyroid carcinoma study, Aug. 10  
Carotid artery: external, Dec. 39  
Catheter (see under Infusion)  
Catheterization  
  with infusion of left gastric to right gastric collateral, Nov. 28  
  selective, for infusion, Nov. 7-8 through stenotic segment of artery, Nov. 16  
Cell(s)  
  basal cell nevoid and cerebellar medulloblastoma, May 8-9  
  beta (see Beta cell)  
  cycle, functional model of, July 33  
  epidermal (see under Epidermal)  
  giant (see Giant cell)  
  hairy (see Hairy cells)  
  HeLa, irradiated, survival curve for, July 34  
  irradiated (see Radiation, cell)  
  islet (see Islet cell)  
  kinetic concepts in radiation, July 20-28  
  kinetic parameters in humans, July 23

markers in hairy cell leukemia, Jan. 17  
 of medulloblastoma, cytogenesis, May 11-12  
 mononuclear, in spleen, Jan. 11  
 null cell adenoma, Feb. 15-16  
 population changes after radiation, graphic representation, July 24  
 responses to radiation, diagrammatic representation, July 17  
 T cell variant in hairy cell leukemia, Jan. 20-21  
 tendosynovial, tumors, Mar. 20-21  
 unirradiated cell population kinetics, July 20-22  
 Central nervous system (see CNS)  
 Cerebellar angiography in medulloblastoma, May 37-39  
 astrocytoma, differential diagnosis, May 37  
 medulloblastoma (see Medulloblastoma, cerebellar)  
 signs in medulloblastoma, May 21  
 syndrome in medulloblastoma, May 23  
 Cerebrospinal fluid cytology in medulloblastoma, May 40  
 polyamine putrescine levels, May 40  
 Cervical: thoracocervical neuroblastoma, in infant, Apr. 31  
 Cervix: adenocarcinoma, uterine artery infusion in, Dec. 28  
 Cervix, carcinoma, Dec. 26-30  
 intra-arterial chemotherapy in, Dec. 27-30  
 chemotherapy, details concerning, Dec. 28  
 complications, Dec. 30  
 results, Dec. 29-30  
 stage IIIB carcinoma, Dec. 29  
 intra-arterial chemotherapy and radiotherapy of complications, Dec. 30  
 results, Dec. 30  
 stage III, gluteal artery occlusion for infusion of, Dec. 21  
 staging system, Dec. 26  
 Chemoembolization, Nov. 20-21  
 Chemotherapy adjuvant, in extremity soft tissue sarcoma, Mar. 31-33  
 trials, Mar. 34  
 combination, in extremity soft tissue sarcoma, Mar. 28-31  
 infusion (see Infusion) in insulinoma, metastatic, Sept. 36-37  
 intra-arterial (see Intra-arterial, chemotherapy)  
 medulloblastoma (see Medulloblastoma, chemotherapy)  
 of neuroblastoma, adrenal, Apr. 22  
 of renal carcinoma, Nov. 47  
 of soft tissue sarcoma of extremity, Mar. 25  
 systemic, Nov. 5  
 toxicity of, June 23-24  
 Children cancer in, three most common, May 6  
 infant neuroblastoma, adrenal, Apr. 20  
 neuroblastoma, adrenal, with hepatic metastases, Apr. 19  
 neuroblastoma, adrenal, CT of, Apr. 22  
 neuroblastoma infiltrating kidney in, Apr. 25  
 neuroblastoma, thoracocervical, Apr. 31  
 medulloblastoma radiotherapy, survival curves after, May 16  
 survival status after radiotherapy, June 19  
 Wilms' tumor lung metastases in 1-year-old, Apr. 17  
 2-year-old, Apr. 14  
 Children's Cancer Study Group and Radiation Therapy Oncology Group Joint

Children's Cancer Study Group  
(cont.)  
Study, June 21  
Chloroethyl nitrosoureas:  
nonglycosylated,  
nephrotoxicity, Oct. 12-13  
Circulation: collateral, in liver  
cancer infusion, Nov.  
27-29  
Cisplatin  
in bladder carcinoma (see  
Bladder carcinoma,  
cisplatin in)  
in brain tumors, Dec. 36-38  
in breast carcinoma, via  
hepatic artery infusion,  
Nov. 40-41  
infusion, femoral arteriography  
before, Dec. 9  
kidney after, Oct. 6, 7, 8  
in metastases of brain tumors,  
Dec. 37-38  
nephrotoxicity of, Oct. 5-9  
toxicities, Dec. 38-39  
CNS  
cancer (see Cancer, CNS)  
tumors, malignant, conditions  
associated with, May 6-7  
Coil: stainless steel, for  
embolization, Nov. 20  
Colon  
carcinoma, Nov. 36-40  
embolization of hepatic  
metastases from, Nov. 31  
hepatic artery infusion in,  
adjuvant, Nov. 37-38  
metastases to pelvis, Nov. 39-40  
Computed (see Tomography,  
computed)  
Concepts (see Radiation, concepts)  
C-peptide: measurement of, Sept.  
9-10  
CSF (see Cerebrospinal fluid)  
CT (see Tomography, computed)  
Cushing's disease, Feb. 14-15  
surgery results, Feb. 15  
Cyclosporin A: nephrotoxicity,  
Oct. 22-23  
Cystitis: bleeding radiation,  
embolization of, Nov. 24  
Cytology: aspiration biopsy, in  
thyroid carcinoma, Aug.  
23-25  
Cytoplasm: of hairy cells, Jan. 6

D  
Dose (see Radiation, dose)  
Drug(s)  
antineoplastic (see  
Antineoplastic drugs)  
dosage adjustment for renal  
insufficiency, Oct. 4-5  
immunosuppressive,  
nephrotoxicity of, Oct.  
3-32  
Duodenal ulcer: embolization in,  
Nov. 22  
Dysmyelopoiesis: in hairy cell  
leukemia, Jan. 26-27  
  
E  
Electron microscopy  
in medulloblastoma, May 14  
transmission, of hairy cells,  
Jan. 5  
Embolization, Nov. 18-21  
of bone metastases from kidney  
carcinoma, Nov. 53  
chemoembolization, Nov. 20-21  
coil for, stainless steel, Nov. 20  
Gelfoam for, Nov. 19  
of giant cell tumors (see Giant  
cell tumors, embolization)  
of head and neck tumors (see  
Head and neck tumors,  
embolization of)  
of hemorrhage  
in radiation cystitis, Nov. 24  
from rectal pouch, Nov. 23  
hepatic artery (see Hepatic  
artery, embolization)  
of hepatic metastases from  
colon carcinoma, Nov. 31  
of hypernephroma in solitary  
kidney, Nov. 52  
Ivalon for, Nov. 19  
in lung metastases, response to,  
Nov. 48  
renal artery (see Kidney,  
carcinoma, renal artery  
embolization)  
of ulcer, duodenal, Nov. 22  
Endocrine  
(See also Multiple endocrine  
neoplasia syndrome)  
functions after radiation, June  
10

status after medulloblastoma treatment, June 33-43

Energy exchange between incident radiation and tissue, July 10

biologic expression of, July 17-19

interaction of radiation with tissue, July 14

Eosinophilic granuloma of bone, Dec. 15-26

methylprednisolone in, intraleisional, Dec. 16-17

results, Dec. 16

technique, Dec. 16

tibia, left, Dec. 17

Ependymoma: differential diagnosis, May 36

Epidermal basal cell monolayer, July 25

cell renewal system, July 22

Etoposide-VP16: in brain tumors, Dec. 38

Extracellular fluid: homeostatic control of, Feb. 6

Extraskeletal tumors, Mar. 21

Extremity hemihypertrophy: after Wilm's tumor surgery, Apr. 7

Extremity: in rhabdomyosarcoma, Apr. 38-39, 40-41

Extremity soft tissue sarcoma, Mar. 3-41

anatomical considerations, Mar. 11

anatomical locations, Mar. 18

benign, Mar. 12

biopsy in, Mar. 13-14

interpretation, Mar. 14-15

chemotherapy, Mar. 25

adjuvant, Mar. 31-33

adjuvant, trials, Mar. 34

with surgery, Mar. 28-31

classification, Mar. 6

pathologic, Mar. 16-17

clinical presentation, Mar. 12-21

etiology, Mar. 5-7

evaluation, clinical, Mar. 15

"fish flesh" consistency of, Mar. 4

frequency, Mar. 18

growth characteristics, local, Mar. 10-12

histogenic theory of, Mar. 6

histogenic variants, frequency, Mar. 20

histologic identification and grade, Mar. 19

histologic types, frequency and characteristics of, Mar. 17-21

historical aspects, Mar. 3-5

immunology, Mar. 8-9

markers, Mar. 9-10

metastatic patterns, Mar. 12

multidisciplinary therapy, Mar. 25-31

multimodality limb salvage program in, Mar. 31

pathologic observations, Mar. 10-11

radiotherapy of, Mar. 24-25

with surgery, Mar. 25-28

with surgery, trials, Mar. 27

"shrinking fields" concept in, Mar. 30

staging, Mar. 16

staging system, Mar. 18

statistics, Mar. 5-7

surgery of, Mar. 22-24

with chemotherapy, combination, Mar. 28-31

with radiotherapy, Mar. 25-28

with radiotherapy, trials, Mar. 27

results, Mar. 23

treatment, Mar. 21-35

of metastases, Mar. 33-35

trials, multimodality, Mar. 32

## F

Facial artery, Dec. 39

Femoral arteriography: before cisplatin infusion, Dec. 9

Fibrosarcoma, Mar. 17-18

Fibrous histiocytoma: malignant, Mar. 19-20

"Fish flesh" consistency: of soft tissue sarcoma, Mar. 4

Fluid: extracellular, homeostatic control of, Feb. 6

5-Fluorouracil (see Bladder carcinoma, 5-fluorouracil in)

Fossa: posterior, tumor,  
symptoms and signs of,  
May 19-21

G

Gait: unsteadiness in  
medulloblastoma, May 23

Gas: after renal artery  
embolization, Nov. 49-50

Gastroduodenal artery: occlusion  
in hepatic arterial infusion  
chemotherapy, Nov. 14

Gastrointestinal hemorrhage:  
infusion for control, Nov.  
22-23

Gelfoam: for embolization, Nov.  
19

Genitourinary hemorrhage:  
infusion for control, Nov.  
23

Giant cell tumors, Dec. 12-15  
embolization of, Dec. 13-15  
results, Dec. 14-15  
technique, Dec. 13-14  
sacral, iliac angiography of,  
Dec. 15

Glioblastoma multiforme: of  
parietal lobe, Dec. 37

Glucose  
levels after fasting and calcium  
stimulation, Sept. 12

monitoring, intraoperative  
plasma, Sept. 34-35

Gluteal artery: occlusion for  
infusion in carcinoma of  
cervix, Dec. 21

Goiter, Aug. 4

Gonadal-hypothalamic-pituitary  
axis  
in female, Feb. 9  
in male, Feb. 8

Gonadotropin: chorionic, in  
hyperinsulinism, Sept. 10

Granuloma (see Eosinophilic  
granuloma)

Growth  
hormone-hypothalamic-  
pituitary-growth axis,  
Feb. 9

after medulloblastoma  
treatment, June 31-33  
problems after radiation,  
June 9

H

Hair loss: after radiation, June 9

Hairy cell(s)  
cytoplasm of, Jan. 6

infiltrates of, portal and  
sinusoidal, Jan. 13

leukemia (see below)

microscopy of  
electron, transmission, Jan. 5  
light, Jan. 4

Hairy cell leukemia, Jan. 3-33  
bone core biopsy in, Jan. 8

cell of origin in, Jan. 17-21

cellular markers in, Jan. 17

complications, Jan. 27  
infectious, Jan. 24

cytochemistry, Jan. 4-7

cytology, Jan. 4-7

diagnosis, differential, Jan. 9

dysmyelopoiesis in, Jan. 26-27

family, Jan. 27-28

future directions, Jan. 33-34

host immunity alteration in,  
Jan. 21-23

immune disorders and, Jan. 26

infection in, Jan. 23-26  
commonly identified  
organisms, Jan. 24

mycobacterial, Jan. 25

liver in, Jan. 13-14

marrow in, Jan. 7-11

presentation  
clinical, Jan. 14-17  
laboratory values at, Jan. 16  
physical findings at, Jan. 15

presenting symptoms, Jan. 15

spleen in, Jan. 11-13

T cell variant in, Jan. 20-21

tissue involvement in, Jan.  
7-14

treatment, Jan. 28-33  
response, Jan. 33

Head  
and neck tumors (see below)

rhabdomyosarcoma, Apr. 35-36

nonparameningeal, Apr. 40

Head and neck tumors, Dec.  
39-47

embolization of, Dec. 42-45

complications, Dec. 44-45

technical considerations, Dec.  
43-44

intra-arterial chemotherapy of, Dec. 40-42  
complications, Dec. 42  
occlusion for infusion, Dec. 41-42  
results, Dec. 42  
technique, Dec. 41-42  
vascular supply, Dec. 39-40  
Headaches: in medulloblastoma, May 22-23  
Hearing loss: sensory, after radiation, June 10  
HeLa cells: irradiated, survival curve, July 34  
Hemihypertrophy: of extremity after Wilms' tumor surgery, Apr. 7  
Hemolytic-uremic syndrome: mitomycin C-induced, kidney after, Oct. 19, 20, 21  
Hemorrhage  
control, infusion in, Nov. 21-23  
gastrointestinal hemorrhage, Nov. 22-23  
genitourinary hemorrhage, Nov. 23  
of radiation cystitis, embolization of, Nov. 24  
from rectal pouch, embolization in, Nov. 23  
Heparinization: systemic, and bladder carcinoma, Dec. 22  
Hepatic (*See also Liver*)  
Hepatic artery  
embolization, Nov. 30-35  
in breast carcinoma, Nov. 41-42  
complications, Nov. 33  
contraindications, Nov. 33-34  
indications, Nov. 32  
with infusion in hepatoma, Nov. 37  
for liver metastases from lung carcinoid, Nov. 44  
side effects, Nov. 32-33  
technique, Nov. 30-32  
infusion, Nov. 30  
adjuvant, in colorectal carcinoma, Nov. 37-38  
in apudoma, complications, Nov. 43  
in apudoma, results, Nov. 43  
in breast carcinoma, Nov. 40-41  
with embolization in hepatoma, Nov. 37  
gastroduodenal artery occlusion in, Nov. 14  
for liver metastases from breast carcinoma, Nov. 42  
occlusion, portal vein infusion after, Nov. 34-35  
redistribution for hepatic infusion chemotherapy, Nov. 12  
Hepatocellular carcinoma, Nov. 35-36  
Hepatoma: hepatic artery infusion and embolization in, Nov. 37  
Hereditary factors  
in cerebellar medulloblastoma, May 8-9  
in CNS cancer, May 7  
Histiocytoma: malignant fibrous, Mar. 19-20  
Homeostatic control  
of blood volume, Feb. 7  
of extracellular fluid, Feb. 6  
Hormone(s)  
antidiuretic, Feb. 6  
growth hormone-hypothalamic-pituitary axis, Feb. 9  
-producing metastases to liver, Nov. 42-43  
therapy of renal carcinoma, Nov. 46-47  
Host immunity: alteration in hairy cell leukemia, Jan. 21-23  
Hydrocephalus, irreversible, in medulloblastoma, May 28  
incidence and prognosis in, May 29  
surgery, May 29  
Hydroxyurea: nephrotoxicity, Oct. 16  
Hyperinsulinemic hypoglycemia: in newborn, Sept. 32-34  
Hyperinsulinism, Sept. 4-43  
clinical presentation, Sept. 5  
endogenous, Sept. 18  
hyperplasia in, Sept. 22  
laboratory features, Sept. 7-13

Hyperinsulinism (*cont.*)  
pathology, Sept. 17-28  
pathophysiology, Sept. 17-28  
pharmacologic control, Sept.  
35-36  
preoperative localization, Sept.  
13-17  
stimulation tests in, Sept.  
11-13  
suppression tests in, Sept.  
10-11  
surgical complications, Sept. 35  
surgical management of, Sept.  
31-35  
Hypernephroma: in solitary  
kidney, embolization of,  
Nov. 52  
Hyperplasia  
beta islet cell, Sept. 21  
in hyperinsulinism, Sept. 22  
Hypertension: after renal artery  
embolization of carcinoma,  
Nov. 49  
Hypoglycemia  
diagnosis, differential, Sept.  
5-7  
fasting, Sept. 6-7  
hyperinsulinemic, in newborn,  
Sept. 32-34  
in hyperinsulinism, Sept. 7-8  
postabsorptive, Sept. 5-6  
Hypothalamic  
-pituitary-adrenal axis, Feb. 8  
-pituitary-gonadal axis  
in female, Feb. 9  
in male, Feb. 8  
-pituitary-growth hormone axis,  
Feb. 9  
-pituitary-prolactin axis, Feb.  
10  
-pituitary-thyroid axis, Feb. 7

## I

Iliac  
angiography, of sacral giant  
cell tumor, Dec. 15  
artery, infusion by, Nov. 13  
Imaging (*see* Scan)  
Immune disorders: and hairy cell  
leukemia, Jan. 26  
Immunity: host, alteration in  
hairy cell leukemia, Jan.  
21-23

Immunology: and extremity soft  
tissue sarcoma, Mar. 8-9  
Immunosuppressive drugs:  
nephrotoxicity of, Oct.  
3-32  
Immunotherapy: of renal  
carcinoma, Nov. 47  
Infant (*see* Children, infant)  
Infarction: in cancer, Nov. 4-62,  
Dec. 4-55  
Infusion, Nov. 4-62, Dec. 4-55  
administration  
choice, Nov. 10-11  
frequency, Nov. 10-11  
in cancer, Dec. 4-55  
catheter  
displacement of, Nov. 15  
fixation, Nov. 8  
position monitoring, Nov. 9  
catheterization for  
left gastric to right gastric  
collateral, Nov. 28  
selective, Nov. 7-8  
chemotherapy delivery, Nov.  
9-10  
complications of, Nov.  
13-17  
flow, pulsatile vs. nonpulsatile,  
Nov. 12-13  
in hemorrhage control, Nov.  
21-23  
gastrointestinal, Nov.  
22-23  
genitourinary, Nov. 23  
hepatic artery (*see* Hepatic  
artery)  
hepatic, hepatic arterial  
redistribution for, Nov. 12  
by iliac artery, Nov. 13  
infection complicating, Nov.  
16-17  
intra-arterial (*see* Intra-  
arterial, infusion)  
in liver cancer (*see* Liver  
cancer, infusion in)  
occlusion-infusion, Nov. 17  
occlusion for, selective, Nov.  
11-12  
portal, Nov. 8-9  
portal vein, after hepatic artery  
occlusion, Nov. 34-35  
redistribution of vascular  
supply, Nov. 11  
techniques, Nov. 7-17

thrombogenic environment for, Nov. 8  
vascular trauma complicating, Nov. 13-15  
Insulin  
antibodies, measurement of, Sept. 9-10  
after fasting and calcium stimulation, Sept. 12  
immunoreactive, Sept. 8-9  
Insulinoma  
immunocytochemical findings in, Sept. 27  
metastatic, chemotherapy, Sept. 36-37  
Intellectual development by age, and medulloblastoma treatment, June 40  
status after medulloblastoma treatment, June 39-41  
International Society of Pediatric Oncology Study, June 21  
Intestinal hemorrhage: infusion for control, Nov. 22-23  
Intra-arterial chemotherapy  
of angiomyxoma of nasopharynx, Dec. 46-47  
of bladder carcinoma (*see* Bladder carcinoma, intra-arterial chemotherapy of)  
in brain tumors (*see* Brain, tumors, intra-arterial chemotherapy of)  
of cervix, carcinoma (*see* Cervix, carcinoma, intra-arterial chemotherapy in)  
of head and neck tumors (*see* Head and neck tumors, intra-arterial chemotherapy of)  
in melanoma (*see* Melanoma, intra-arterial chemotherapy of)  
of osteosarcoma (*see* Osteosarcoma, intra-arterial chemotherapy of)  
infusion, Nov. 5-17  
antineoplastic agents for, Nov. 6-7  
cytotoxic agents delivered by, Nov. 6  
rationale, Nov. 5-7

Intracranial pressure: in medulloblastoma, May 19-20  
Irradiation (*see* Radiation)  
Ischium: osteogenic sarcoma of, Nov. 13  
Islet cell  
adenoma (*see* Adenoma, islet cell)  
carcinoma, beta, Sept. 35  
hyperplasia, beta, Sept. 21  
Isodose  
curves, radiation, historical review, June 13  
distribution, June 7  
Isoeffect (*see* Radiation, isoeffect)  
Isolation-perfusion: in cancer, Nov. 17-18  
Isotopic monitoring: of flow distribution in intra-arterial chemotherapy, Dec. 22  
Italian Child's Neuro-oncology Group Study, June 22  
Ivalon: for embolization, Nov. 19

## K

Kidney  
abscess after renal artery embolization, Nov. 49-50  
carcinoma, Nov. 45-52  
bone metastases from, embolization of, Nov. 53  
chemotherapy, Nov. 47  
hormonal therapy, Nov. 46-47  
immunotherapy, Nov. 47  
liver metastases from, Nov. 54  
nephrectomy in, Nov. 45  
regression, spontaneous, Nov. 46  
renal artery embolization (*see* below)  
skeletal metastases from, Nov. 53-54  
carcinoma, renal artery embolization, Nov. 47-52  
complications, Nov. 49-50  
immunologic aspects of, Nov. 50-52  
results, Nov. 47-49

**Kidney (cont.)**  
unintentional embolization, Nov. 50  
carcinoma, in solitary kidney, Nov. 52-53  
after cisplatin, Oct. 6, 7, 8  
insufficiency, drug dosage adjustment for, Oct. 4-5  
after mitomycin C-induced hemolytic-uremic syndrome, Oct. 19, 20, 21  
neuroblastoma infiltrating, in infant, Apr. 25  
shutdown after renal embolization, Nov. 49  
solitary carcinoma in, Nov. 52-53  
hypernephroma, embolization of, Nov. 52  
Wilms' tumor, Apr. 9  
stage I, Apr. 6  
**Kinetic(s)**  
parameters in humans, cell, July 23  
unirradiated cell population, July 20-22

## L

L-asparaginase: nephrotoxicity, Oct. 16  
Leptomeningeal tumor deposits: CT of, May 35  
Leukemia (*see* Hairy cell leukemia)  
Light microscopy: of hairy cells, Jan. 4  
Linear energy transfer, July 16  
radiation and, July 16  
Lingual artery, Dec. 39  
Liposarcoma, Mar. 17  
CT of, Mar. 16  
Liver  
(*See also* Hepatic)  
cancer, infusion in, Nov. 23-36  
anatomical considerations, Nov. 25-27  
collateral circulation for therapy, Nov. 27-29  
criteria for response, Nov. 27-29  
rationale for intra-arterial approach, Nov. 25

carcinoma, hepatocellular, Nov. 35-36  
in hairy cell leukemia, Jan. 13-14  
metastases  
from adrenal neuroblastoma, Apr. 19  
from breast carcinoma, Nov. 40  
from breast carcinoma, hepatic artery infusion in, Nov. 42  
from colon carcinoma, embolization of, Nov. 31  
hormone-producing, Nov. 42-43  
from kidney carcinoma, Nov. 54  
from lung carcinoid, hepatic artery embolization in, Nov. 44  
nonresectable, Nov. 38-39  
resectable, Nov. 38  
Lobectomy: in thyroid carcinoma, Aug. 5  
**Lung**  
carcinoïd, liver metastases from, hepatic artery embolization in, Nov. 44  
metastases  
response to embolization and nephrectomy, Nov. 48  
in Wilms' tumor, in infant, Apr. 17

## M

Marrow: in hairy cell leukemia, Jan. 7-11  
Maxillary artery, Dec. 39  
Medulloblastoma, May 4-54  
advanced stage, May 45-46  
air studies in, May 39  
angiography of, cerebellar, May 37-39  
biologic behavior, May 15  
biologic characteristics, May 15-17  
bone scans in, May 40  
brain scan in, May 37  
cells, cytogenesis of, May 11-12  
cerebellar  
clinical manifestations, May 21-24

familial occurrence, May 7-9  
familial occurrence, isolated, May 7-8  
hereditary factors in, May 8-9  
onset mode in, May 21  
symptomatology, May 21  
cerebellar syndrome in, May 23  
chemotherapy of, May 32, June 18-24  
current, analysis of, June 29-30  
with radiotherapy, survival, June 20  
toxicity of, June 23-24  
clinical course, May 17-19  
CT of, May 33-36  
with no contrast infusion, May 34-35  
follow-up, May 35-36  
with intravenous contrast infusion, May 35  
leptomeningeal tumor  
deposits, May 35  
in pattern II, May 44  
in stage I, May 44  
stage III, May 46  
thin hypodense zone in, May 35  
cystic components of, May 35  
cytogenesis of cells, May 11-12  
cytology, CSF, May 40  
desmoplastic variant, May 14-15  
diagnosis, May 32-51  
clinical, May 32-33  
differential, May 36-40  
diagnostic studies, May 33-40  
early stage, May 42-43  
epidemiology, May 5-11  
etiology, May 5-6  
extent, and prognosis, May 27-28  
future for, directions for, June 43-45  
gait unsteadiness in, May 23  
headaches in, May 22-23  
histologic characteristics, May 15  
histology, May 31-32  
histopathology, May 12-14  
hydrocephalus in, irreversible, May 28  
incidence and prognosis, May 29  
incidence, May 9-11  
age, May 9  
sex, May 9-10  
invasive, May 47-48  
localized, May 46  
location, May 10-11  
by age, May 11  
incidence by site and age, May 10  
prognosis and, May 27-28  
management  
therapeutic, June 4-25  
therapeutic, of primary tumor, June 6-24  
manifestations, clinical, May 22  
meningeal invasion by, May 15  
metastatic, May 48  
microscopic histology of, May 12-13  
microscopic picture of, May 13  
myelography in  
CT-assisted, May 39  
positive, in stage IV, May 47  
in spinal metastases, May 39  
for staging procedures, May 50-51  
natural history, May 17-32  
neighborhood syndrome in, May 24  
neurosurgery in, June 6  
nuclear magnetic resonance  
imaging of, May 37  
papilledema in, May 23  
pathology, May 11-17  
gross, May 12  
pressure syndrome in, May 21  
prognosis  
age in, May 30  
factors influencing, May 27  
sex in, May 30-31  
radiation dose and clinical  
recurrences, May 24  
radiography of, skull, May 40  
radiosensitivity, May 16  
radiotherapy, June 6-18  
basic principles, June 7-8  
with chemotherapy, survival, June 20  
in children, survival curves, May 16  
dose for, June 14-18

Medulloblastoma (*cont.*)  
dose, survival status after,  
    June 18  
high-dose, June 16  
isodose distribution, June 7  
low-dose, June 15-16  
method, June 8-9  
optimum megavoltage  
    radiotherapeutic  
    techniques, June 15  
physiologic development  
    after, June 32  
postoperative, May 27  
survival after, in children,  
    June 19  
survival curves after, May 19  
survival rates after, May 27  
technique, June 11-14  
technique, survival curves in  
    early medulloblastoma and,  
    May 43  
technique, survival status  
    after, by age and sex, May  
    31  
at University of Kentucky,  
    June 14  
recurrent, retreatment for,  
    June 24-25  
results of treatment, June  
    25-43  
    functional, June 30-43  
    performance, June 30-43  
shunting procedures in, May  
    28-29  
stage I, May 42-43  
    CT of, May 44  
stage II, May 43-45  
    CT of, May 44  
stage III, May 45-46  
    CT of, May 46  
    with subarachnoid  
        metastases, May 48  
stage IV, May 46  
staging investigation, proposed  
    neurodiagnostic, May 49  
staging procedures, May 48-51  
staging system, May 40-48  
    CT in, May 46-48  
subtypes, May 14-15  
survival in, May 28, June  
    25-29  
    historical review, June 25-26  
    with modern therapy, June  
    26-29  
past and present, June 26  
personal data in, June 30  
status by age and sex, May  
    31  
after treatment,  
    psychologist's comments on  
    survivors, June 41-43  
tissue culture in, May 16-17  
treatment  
    failure, expected pattern in  
    future, May 26-27  
    failure pattern, May 24-27  
    failure, radiation dose and,  
    May 24-25  
    failure, sites of, May 24  
    physical development after,  
    June 34-35  
    physical status after, June 31  
vomiting in, May 22  
Melanoma, Dec. 31-33  
    angiography of, Dec. 31-33  
    intra-arterial chemotherapy of,  
    Dec. 31-32  
    complications, Dec. 32  
    response criteria, Dec. 31  
    results, Dec. 31-32  
pelvic, Dec. 33  
vulvar, Dec. 32-33  
Meninges: invasion by  
    medulloblastoma, May 15  
Mental retardation: after  
    radiation, June 10  
Metastases  
    bone, from kidney carcinoma,  
        embolization of, Nov. 53  
    of brain tumors, cisplatin in,  
    Dec. 37-38  
    colorectal, to pelvis, Nov. 39-40  
    extra-CNS, and  
        medulloblastoma treatment  
        failure, May 25-26  
    in extremity soft tissue  
        sarcoma, Mar. 33-35  
    of insulinoma, chemotherapy,  
        Sept. 36-37  
liver, (see Liver, metastases)  
lung (see Lung, metastases)  
of medulloblastoma, May 48  
of neuroblastoma, surgery for,  
    Apr. 28  
skeletal, from kidney  
    carcinoma, Nov. 53-54  
of soft tissue sarcoma of  
    extremity, Mar. 12

spinal (see Spinal metastases)  
subarachnoid, in  
medulloblastoma, May 48  
of Wilms' tumor (see Wilms' tumor, metastases of)  
Methotrexate: nephrotoxicity, Oct. 13-15  
Methylprednisolone (see Eosinophilic granuloma of bone, methylprednisolone)  
Microscopic histology: of medulloblastoma, May 12-13  
Microscopic picture: of medulloblastoma, May 13  
Microscopy  
electron (see Electron microscopy)  
light, of hairy cells, Jan. 4  
Microsurgery: transsphenoidal, of pituitary adenoma, Feb. 11  
Mithramycin: nephrotoxicity, Oct. 20-21  
Mitomycin C  
-induced hemolytic-uremic syndrome, kidney after, Oct. 19, 20, 21  
nephrotoxicity, Oct. 18-20  
Mitotic cycle: position in, and survival after radiation, July 33-35  
Model(s)  
functional, of cell cycle, July 33  
for radiation survival, July 30  
of tissue response to radiation, July 9-14  
Monitoring  
of catheter position for infusion, Nov. 9  
isotopic, of flow distribution in intra-arterial chemotherapy, Dec. 22  
Monolayer: irradiated epidermal basal cell, July 25  
Mononuclear cells: in spleen, Jan. 11  
Mortality: in thyroid carcinoma, Aug. 16-19  
Multiple endocrine neoplasia syndromes, type I  
pituitary adenoma in, Feb. 17  
sequence of systems, Feb. 17  
Mycobacterial infection: in hairy cell leukemia, Jan. 25

Myelography  
CT-assisted, in  
medulloblastoma, May 39  
in medulloblastoma (see Medulloblastoma, myelography)  
of spinal metastases in medulloblastoma, May 39  
Myelosuppression: after radiation, June 10

N

Nasopharynx (see Angiofibroma of nasopharynx)  
Nausea: after radiation, June 9-10  
Neck  
radiotherapy, in thyroid carcinoma, Aug. 20  
in rhabdomyosarcoma, Apr. 35-36  
nonparameningeal, Apr. 40  
tumors (see Head and neck tumors)  
Neighborhood syndrome: in medulloblastoma, May 24  
Nelson's syndrome, Feb. 14-15  
Neoplasia (see Tumors)  
Nephrectomy  
with embolization in lung metastases, response to, Nov. 48  
in renal carcinoma, Nov. 45  
in Wilms' tumor  
with lung metastases, in infant, Apr. 17  
stage II, Apr. 8  
Nephroblastoma (see Wilms' tumor)  
Nephrotoxicity  
alkylating agents, Oct. 5-10  
anthracyclines, Oct. 18  
antimetabolites, Oct. 13-18  
of antineoplastic agents, Oct. 3-32  
antitumor antibiotics, Oct. 18-21  
5-azacytidine, Oct. 15  
of cisplatin, Oct. 5-9  
cyclosporin A, Oct. 22-23  
hydroxyurea, Oct. 16  
of immunosuppressive agents, Oct. 3-32

Nephrotoxicity (cont.)  
L-asparaginase, Oct. 16  
methotrexate, Oct. 13-15  
mithramycin, Oct. 20-21  
mitomycin C, Oct. 18-20  
nitrosoureas, nonglycosylated  
    chloroethyl, Oct. 12-13  
nitrosoureas, Oct. 10-13  
oxazaphosphorines, Oct. 9-10  
plant alkaloids, Oct. 21-22  
plant derivatives, Oct. 21-23  
purine analogues, Oct. 17-18  
streptozocin, Oct. 10-12  
teniposide, Oct. 22

Nervous system (see CNS)  
Nesidioblastosis, Sept. 21-26  
    abnormal events in pancreas  
        leading to, Sept. 25

Neuroblastoma, Apr. 18-30  
    adrenal  
        CT of, in infant, Apr. 22  
        hepatic metastases from, Apr.  
            19  
        pyelography in, intravenous,  
            in infant, Apr. 20  
    CT in, Apr. 21  
    diagnosis, Apr. 18-21  
    future of, Apr. 28-30  
    infiltrating kidney, in infant,  
        Apr. 25  
    metastases of, surgery for, Apr.  
        28  
    recommendations for, current,  
        Apr. 28-30  
    staging, Apr. 21-23  
    staging systems, Apr. 23  
    surgery of, Apr. 23-28  
        delayed primary operation,  
            Apr. 27  
        second looks, Apr. 27  
    thoracocervical, in infant, Apr.  
        31  
    treatment, Apr. 5  
        nonoperative, Apr. 28

Neurologic impairment: localized,  
    in medulloblastoma, May  
        20

Neurosurgery: in  
    medulloblastoma, June 6

Neutrons, fast, for radiotherapy,  
    July 50-53  
    incidence of survival after, July  
        51

70

Nevoid: basal cell, and cerebellar  
    medulloblastoma, May 8-9

Newborn: hyperinsulinemic  
    hypoglycemia, treatment,  
        Sept. 32-34

Nitrosoureas: nonglycosylated  
    chloroethyl, nephrotoxicity,  
        Oct. 12-13

Nitrosoureas: nephrotoxicity of,  
    Oct. 10-13

Nuclear magnetic resonance  
    imaging: of  
        medulloblastoma, May 37

Null cell adenoma, Feb. 15-16

O

Occipital artery, Dec. 39

Occlusion-infusion, Nov. 17

Orbit: in rhabdomyosarcoma,  
    Apr. 40

Osteogenic sarcoma: of ischium,  
    Nov. 13

Osteosarcoma, Dec. 5-12  
    intra-arterial chemotherapy of,  
        Dec. 6-12  
    chemotherapeutic agents for,  
        Dec. 7  
    results, Dec. 12  
    technical considerations, Dec.  
        7-10  
    staging system, Mar. 18

Otitis: media and externa, after  
    radiation, June 10

Oxazaphosphorines:  
    nephrotoxicity, Oct. 9-10

Oxygen: in radiation response,  
    July 36-37

P

Pain palliation: in bone  
    metastases, Nov. 53

Pancreas  
    abnormal events leading to  
        nesidioblastosis, adenoma,  
        and islet cell hyperplasia,  
        Sept. 25  
    adenoma, beta cell, solitary,  
        Sept. 18  
    adenomatosis, beta cell, Sept.  
        18-21  
    carcinoma, beta cell, Sept. 18  
    head, venography of, Sept. 16

tumors, mixed endocrine, Sept. 26-28  
 Papilledema: in medulloblastoma, May 23  
 Parameningeal: rhabdomyosarcoma, Apr. 40  
 Parietal lobe: glioblastoma multiforme of, Dec. 37  
 Pelvis: colorectal metastases to, Nov. 39-40  
 melanoma, Dec. 33  
 Perineal embryonal rhabdomyosarcoma: cytology of, Apr. 33  
 Perineum: in rhabdomyosarcoma, Apr. 40-41  
 Pharyngeal artery, Dec. 39  
 Physical status: after therapy of medulloblastoma, June 31  
 Pituitary: adenoma, Feb. 5-26  
     classification, Feb. 10  
     multiple endocrine neoplasia syndromes and, Feb. 17  
     adenoma, surgery of, Feb. 5-26  
     microsurgery,  
         transphenoidal, Feb. 11  
     procedure, Feb. 21-26  
     steps of combined method favored by author, Feb. 20-21  
     transsphenoidal methods of access, Feb. 18-20  
     -hypothalamic-adrenal axis, Feb. 8  
     -hypothalamic-gonadal axis  
         in female, Feb. 9  
         in male, Feb. 8  
     -hypothalamic-growth hormone axis, Feb. 9  
     -hypothalamic-prolactin axis, Feb. 10  
     -hypothalamic-thyroid axis, Feb. 7  
     lesion in acromegaly, immunocytochemistry of, Feb. 13  
     tumors, therapy goals, Feb. 10  
 Plant alkaloids, nephrotoxicity, Oct. 21-22  
     derivatives, nephrotoxicity of, Oct. 21-23  
 Portal infiltrates: of hairy cells, Jan. 13  
 Portal vein: infusion after hepatic artery occlusion, Nov. 34-35  
 Postembolization syndrome, Nov. 49  
 Posterior fossa tumor: symptoms and signs of, May 19-21  
 Pressure syndrome: in medulloblastoma, May 21  
 Proinsulin, Sept. 10  
 Prolactin: adenoma, Feb. 13-14  
     surgery results, Feb. 14  
     -hypothalamic-pituitary axis, Feb. 10  
 Prostate: in rhabdomyosarcoma, Apr. 40  
     tumors, and rhabdomyosarcoma, Apr. 36-38  
 Psychoeducational evaluation: after medulloblastoma treatment, June 41  
 Psychologist's comments: on medulloblastoma survivors, June 41-43  
 Purine analogues: nephrotoxicity, Oct. 17-18  
 Pyelography, intravenous in adrenal neuroblastoma, Apr. 20  
     of Wilms' tumor, stage II, Apr. 8

## R

Radiation  
 (See also Radiography, Radiotherapy)  
 action mechanism, July 14-16  
 in cancer, July 3-36  
     critical concepts, July 12-13  
     example, clinical, July 6-8  
 cell  
     dose-survival response, factors modifying, July 32-39  
     irradiated HeLa cell, survival curve, July 34

Radiation (cont.)

- cell population changes produced by, graphic representation, July 24
- cell responses to, diagrammatic representation, July 17
- cell survival, July 27-28
- concepts
  - biologic, July 17-20
  - cell kinetic, July 20-27
  - curves, July 30
  - dependence on radiation dose, July 28-32
  - physical aspects, July 14-16
  - radiobiologic concepts, July 27-39
- cystitis, hemorrhage of, embolization of, Nov. 24
- dose
  - dependence of cell survival on, July 28-32
  - medulloblastoma failure and, May 24-25
  - in medulloblastoma, and recurrences, May 24
  - in medulloblastoma, and spinal metastases, May 25
  - optimum, June 16-18
  - survival curves according to, June 17
  - time-dose isoeffect and, July 42-45
  - time-dose relationships, and multi-exposure schedules, July 39-45
- effects on normal tissue, June 9-11
- epidermal basal cell monolayer, July 25
- injury, repair of, July 37-39
- interaction of radiation with target molecules, schematic diagram, July 15
- with tissue, energy exchange in, July 14
- isodose curves, historical review, June 13
- isoeffect
  - empirical, July 41-42
  - plots for skin, July 43
  - time-dose, July 41-42
  - time-dose, dose survival, July 42-45
- linear energy transfer and, July 16
- multi-exposure course of therapy, effect of repair during, July 41
- multi-exposure schedules, and time-dose relationships, July 39-45
- relative biologic effectiveness, July 19-20
- response
  - oxygen in, July 36-37
  - quantification a cell level, July 22-27
- survival
  - cell repair in, July 38
  - models for, July 30
  - position in mitotic cycle, July 33
  - proliferation of cells in, July 36
  - recruitment and, July 33-35
  - redistribution and, July 33-35
  - repopulation, July 35-36
  - time-dose isoeffect and, July 42-45
  - time-dose relationships and multi-exposure schedules, July 39-55
  - tissue response to, model of, July 9-14
- Radiobiologic concepts, July 27-39
- Radiography
  - of bladder carcinoma, Dec. 19
  - skull, in medulloblastoma, May 40
- Radiosensitivity: of medulloblastoma, May 16
- Radiotherapy, July 46-53
- cancer
  - dose survival parameters, July 32
  - effectiveness for different cancers, July 47
- of cervical carcinoma (see Cervix, carcinoma, intra-arterial chemotherapy and radiotherapy in)
- of extremity soft tissue sarcoma, Mar. 24-25
- high-LET, July 50-53
- machines, evolution of, June 8

in medulloblastoma (*see* medulloblastoma, radiotherapy)

of neck in thyroid carcinoma, Aug. 20

neutrons for, fast, July 50-53

incidence of survival after, July 51

of soft tissue sarcoma of extremity with surgery, Mar. 25-28

trials, Mar. 27

time-dose  
(*See also* dose, time-dose above)

accelerated fractionation, July 48-49

fractionation schedules, July 47-50

hyperfractionation, July 49-50

standard, July 47-48

Rectosigmoid carcinoma:

hemorrhage in, embolizations of, Nov. 23

Rectum

carcinoma, Nov. 36-40

hepatic artery infusion in, adjuvant, Nov. 37-38

metastases to pelvis, Nov. 39-40

pouch, hemorrhage from, embolization in, Nov. 23

Renal (*see* Kidney)

Rhabdomyosarcoma, Mar. 21, Apr. 30-40, Dec. 43

bladder in, Apr. 40

bladder tumors and, Apr. 36-38

diagnosis, Apr. 30-32

extremity in, Apr. 38-39, 40-41

future of, Apr. 39-41

head in, Apr. 35-36

nonparameningeal, Apr. 40

Intergroup Study

findings, Apr. 35-39

staging system, Apr. 33

neck in, Apr. 35-36

nonparameningeal, Apr. 40

orbit, Apr. 40

parameningeal, Apr. 40

perineal embryonal, cytology of, Apr. 33

perineum in, Apr. 40-41

prostate in, Apr. 40

prostate tumors and, Apr. 36-38

recommendations, current, Apr. 39-41

relapse, Apr. 39

staging, Apr. 32-34

testicular, Apr. 40

treatment, Apr. 5, 34-35

trunk in, Apr. 38-39, 40-41

vulvovaginal, Apr. 40

## S

Sacral giant cell tumor: iliac angiography of, Dec. 15

### Sarcoma

- associated antigens in urine, evaluation, Mar. 9
- extremity (*see* Extremity soft tissue sarcoma)
- fibrosarcoma, Mar. 17-18
- liposarcoma, Mar. 17
- Ct of, Mar. 16
- osteogenic, of ischium, Nov. 13
- osteosarcoma (*see* Osteosarcoma)
- rhabdomyosarcoma (*see* Rhabdomyosarcoma)
- soft tissue (*see* Extremity soft tissue sarcoma)
- undifferentiated, Mar. 21

### Scanning

- bone, in medulloblastoma, May 40
- brain, in medulloblastoma, May 37
- nuclear magnetic resonance, of medulloblastoma, May 37
- thyroid, in thyroid carcinoma, Aug. 22-23
- results, Aug. 22

### Sex

- incidence in medulloblastoma, May 9-10
- in medulloblastoma prognosis, May 30-31
- thyroid carcinoma survival by, Aug. 43-44

### Shunting procedures: in

- medulloblastoma, May 28-29

Sinusoidal infiltrates: of hairy cells, Jan. 13  
 Skeletal metastases: from kidney carcinoma, Nov. 53-54  
 Skin  
     isoeffect plots for, radiation, July 43  
     reactions to radiation, June 9  
 Skull radiography: in medulloblastoma, May 40  
 Soft tissue (see Extremity soft tissue sarcoma)  
 Southwest Oncology Group Study Trial, June 19-21  
 Spinal metastases  
     in medulloblastoma failure, May 25  
     myelography of, May 39  
 Spleen  
     in hairy cell leukemia, Jan. 11-13  
     mononuclear cells, in, Jan. 11  
 Stature: after medulloblastoma treatment, June 31-33  
 Stenotic segment: of artery, catheterization through, Nov. 16  
 Stomach: hemorrhage control, infusion for, Nov. 22-23  
 Streptozocin: nephrotoxicity of, Oct. 10-12  
 Subarachnoid metastases: in medulloblastoma, May 48  
 Subtemporal operation, Feb. 26  
 Swiss Pediatric Oncology Group Study Trial, June 21-22  
 Synovial: tendosynovial cell tumors, Mar. 20-21

T

T cell variant: in hairy cell leukemia, Jan. 20-21  
 Temporal artery, Dec. 39  
 Tendosynovial cell tumors, Mar. 20-21  
 Teniposide nephrotoxicity, Oct. 22  
 Testicular rhabdomyosarcoma, Apr. 40  
 Thoracocervical neuroblastoma: in infant, Apr. 31  
 Thyroglobulin: in thyroid cancer, Aug. 25  
 Thyroid  
     cancer, thyroglobulin levels in, Aug. 25  
     carcinoma (see below)  
     disorders, possible, prevalence of, Aug. 14-15  
     -hypothalamic-pituitary axis, Feb. 7  
     nodule, solitary  
         palpable, thyroid carcinoma in, frequency, Aug. 18  
         surgery for, Aug. 13-14  
     scan in thyroid carcinoma, Aug. 22-23  
         results, Aug. 22  
     screening in healthy women, Aug. 12-13  
 Thyroid carcinoma, Aug. 4-49  
     abbreviations relating to, Aug. 4-5  
     biopsy cytology in, aspiration, Aug. 23-25  
     city care in, Aug. 10  
     comments on, Aug. 14-44  
     definitions relating to, Aug. 4-5  
     diagnosis  
         age at, Aug. 26  
         histopathologic, after surgery of solitary nodule, Aug. 13  
         new, 1960-1977, Aug. 11  
         distribution by histologic type, Aug. 29, 31  
         epidemiologic aspects, Aug. 14-19  
         etiology, Aug. 19-25  
         evaluation, clinical, Aug. 19-25  
         familial disposition, Aug. 19-20  
         follicular, Aug. 27  
         frequency in palpable solitary nodule, Aug. 18-19  
         health care in, Aug. 10  
         histopathology, Aug. 25-29  
         history in, Aug. 21-22  
         incidence, Aug. 16-19  
             age-specific, Aug. 17  
             by histologic type, Aug. 29  
         material of study, Aug. 10-14  
         methods of study, Aug. 10-14  
         mortality in, Aug. 16-19  
         outcome

with palliative treatment, Aug. 30  
with treatment for cure, Aug. 30

palpable disorders, prevalence, Aug. 14-15

papillary, Aug. 27

physical examination in, Aug. 21-22

prevalence, Aug. 15-16

radiotherapy of neck in, Aug. 20

recurrence, Aug. 32

results, Aug. 14-44  
at follow-up, Aug. 37

statistical methods of study, Aug. 14

subjects of study, Aug. 10-14

summary of study, Aug. 44-46

surgery, Aug. 29-36  
additional therapy in, Aug. 29-30

complications, Aug. 32

procedure, and tumor stage and type, Aug. 31

for solitary thyroid nodule, Aug. 13-14

survival in, Aug. 35-44  
by age, Aug. 42  
for all patients, Aug. 36-38  
by histologic type, Aug. 38-39

by node status, Aug. 41-42

rate, cumulative, Aug. 37

by sex, Aug. 43-44

time in fatal cases, Aug. 35-36

by tumor stage, Aug. 39-40

symptoms, presenting, Aug. 20-21

thyroid scan in, Aug. 22-23  
results, Aug. 22

treatment, Aug. 29-35  
nonsurgical, Aug. 34-35

Thyroidal artery, Dec. 39

Thyroidectomy  
partial, Aug. 5  
total, Aug. 4

Tissue response: to radiation, model of, July 9-14

Tolbutamide test, Sept. 11-12

Tomography, computed assisted myelography in

medulloblastoma, May 39

of liposarcoma, Mar. 16

of medulloblastoma (see Medulloblastoma, CT of)

in neuroblastoma, Apr. 21

adrenal, in infant, Apr. 22

in staging system for medulloblastoma, May 46-48

of trophoblastic tumor, Dec. 38

Toxicity  
of chemotherapy in medulloblastoma, June 23-24

of cisplatin, Dec. 38-39

nephrotoxicity (see Nephrotoxicity)

Trauma: vascular, complicating infusion, Nov. 13-15

Trophoblastic tumor: CT of, Dec. 38

Trunk: in rhabdomyosarcoma, Apr. 38-39, 40-41

Tumors  
bladder, and  
rhabdomyosarcoma, Apr. 36-38

brain (see Brain, tumors)

CNS (see Cancer, CNS)

extraosseous, Mar. 21

giant cell (see Giant cell tumors)

head (see Head and neck tumors)

leptomeningeal, deposits, CT of, May 35

malignant (see Cancer)

multiple endocrine (see Multiple endocrine neoplasia syndromes)

neck (see Head and neck tumors)

pancreas, mixed endocrine, Sept. 26-28

pituitary, therapy goals, Feb. 10

posterior fossa, symptoms and signs of, May 19-21

prostate, and  
rhabdomyosarcoma, Apr. 36-38

tendosynovial cell, Mar. 20-21

trophoblastic, CT of, Dec. 38

Wilms' (see Wilms' tumor)

## U

Ulcer: duodenal, embolization in, Nov. 22

University of Padova Experience, June 22-23

Uremic-hemolytic syndrome: mitomycin C-induced, kidney after, Oct. 19, 20, 21

Urinary hemorrhage: infusion for control, Nov. 23

Urine: sarcoma-associated antigens in, evaluation, Mar. 9

USL of Perugia Experience, June 23

Uterine artery infusion: in adenocarcinoma of cervix, Dec. 28

## V

Vaginal rhabdomyosarcoma, Apr. 40

Vein: portal, infusion after hepatic artery occlusion, Nov. 34-35

Velban: for hepatic artery infusion in breast carcinoma, Nov. 41

Venography: of pancreatic head, Sept. 16

Vessels supply  
in head and neck tumors, Dec. 39-40  
redistribution for infusion, Nov. 11  
trauma complicating infusion, Nov. 13-15

Vinblastine: for hepatic artery infusion in breast carcinoma, Nov. 41

Vomiting  
in cerebellar medulloblastoma, May 22  
after radiation, June 9-10

Vulva: melanoma, Dec. 32-33

Vulvovaginal rhabdomyosarcoma, Apr. 40

## W

Wilms' tumor, Apr. 5-18  
diagnosis, Apr. 5-10  
future for, Apr. 15-18  
of kidney, Apr. 9  
stage I, Apr. 6  
metastases of  
treatment, Apr. 13-15  
in 2-year-old, Apr. 14  
preoperative evaluation, Apr. 5-10  
recommendations for, current, Apr. 15-18  
stage II, intravenous pyelography of, Apr. 8  
staging, Apr. 10-11  
clinicopathologic systems, Apr. 11  
surgery, hemihypertrophy after, Apr. 7  
treatment, Apr. 11-15  
bilateral, Apr. 13-15  
nonoperative, Apr. 15

## X

X-ray (see Radiation)

artery

astoma,

-10

2-33

sarcoma,

5

, Apr.

urrent,

r. 8

ems,

hy